267 related articles for article (PubMed ID: 21458265)
1. RAF inhibitor-induced KSR1/B-RAF binding and its effects on ERK cascade signaling.
McKay MM; Ritt DA; Morrison DK
Curr Biol; 2011 Apr; 21(7):563-8. PubMed ID: 21458265
[TBL] [Abstract][Full Text] [Related]
2. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
[TBL] [Abstract][Full Text] [Related]
3. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
Hatzivassiliou G; Song K; Yen I; Brandhuber BJ; Anderson DJ; Alvarado R; Ludlam MJ; Stokoe D; Gloor SL; Vigers G; Morales T; Aliagas I; Liu B; Sideris S; Hoeflich KP; Jaiswal BS; Seshagiri S; Koeppen H; Belvin M; Friedman LS; Malek S
Nature; 2010 Mar; 464(7287):431-5. PubMed ID: 20130576
[TBL] [Abstract][Full Text] [Related]
4. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
[TBL] [Abstract][Full Text] [Related]
5. CK2 Is a component of the KSR1 scaffold complex that contributes to Raf kinase activation.
Ritt DA; Zhou M; Conrads TP; Veenstra TD; Copeland TD; Morrison DK
Curr Biol; 2007 Jan; 17(2):179-84. PubMed ID: 17174095
[TBL] [Abstract][Full Text] [Related]
6. Stabilization of C-RAF:KSR1 complex by DiRas3 reduces availability of C-RAF for dimerization with B-RAF.
Baljuls A; Dobrzyński M; Rauch J; Rauch N; Kolch W
Cell Signal; 2016 Oct; 28(10):1451-62. PubMed ID: 27368419
[TBL] [Abstract][Full Text] [Related]
7. Signaling dynamics of the KSR1 scaffold complex.
McKay MM; Ritt DA; Morrison DK
Proc Natl Acad Sci U S A; 2009 Jul; 106(27):11022-7. PubMed ID: 19541618
[TBL] [Abstract][Full Text] [Related]
8. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
Poulikakos PI; Persaud Y; Janakiraman M; Kong X; Ng C; Moriceau G; Shi H; Atefi M; Titz B; Gabay MT; Salton M; Dahlman KB; Tadi M; Wargo JA; Flaherty KT; Kelley MC; Misteli T; Chapman PB; Sosman JA; Graeber TG; Ribas A; Lo RS; Rosen N; Solit DB
Nature; 2011 Nov; 480(7377):387-90. PubMed ID: 22113612
[TBL] [Abstract][Full Text] [Related]
9. Ras-mutant cancer cells display B-Raf binding to Ras that activates extracellular signal-regulated kinase and is inhibited by protein kinase A phosphorylation.
Li Y; Takahashi M; Stork PJS
J Biol Chem; 2013 Sep; 288(38):27646-27657. PubMed ID: 23893412
[TBL] [Abstract][Full Text] [Related]
10. MEK drives BRAF activation through allosteric control of KSR proteins.
Lavoie H; Sahmi M; Maisonneuve P; Marullo SA; Thevakumaran N; Jin T; Kurinov I; Sicheri F; Therrien M
Nature; 2018 Feb; 554(7693):549-553. PubMed ID: 29433126
[TBL] [Abstract][Full Text] [Related]
11. Drug discovery: inhibitors that activate.
Cichowski K; Jänne PA
Nature; 2010 Mar; 464(7287):358-9. PubMed ID: 20237552
[No Abstract] [Full Text] [Related]
12. Classical RAS proteins are not essential for paradoxical ERK activation induced by RAF inhibitors.
Lai LP; Fer N; Burgan W; Wall VE; Xu B; Soppet D; Esposito D; Nissley DV; McCormick F
Proc Natl Acad Sci U S A; 2022 Feb; 119(5):. PubMed ID: 35091470
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation regulates KSR1 stability, ERK activation, and cell proliferation.
Razidlo GL; Kortum RL; Haferbier JL; Lewis RE
J Biol Chem; 2004 Nov; 279(46):47808-14. PubMed ID: 15371409
[TBL] [Abstract][Full Text] [Related]
14. Limited Proteolysis Combined with Stable Isotope Labeling Reveals Conformational Changes in Protein (Pseudo)kinases upon Binding Small Molecules.
Di Michele M; Stes E; Vandermarliere E; Arora R; Astorga-Wells J; Vandenbussche J; van Heerde E; Zubarev R; Bonnet P; Linders JT; Jacoby E; Brehmer D; Martens L; Gevaert K
J Proteome Res; 2015 Oct; 14(10):4179-93. PubMed ID: 26293246
[TBL] [Abstract][Full Text] [Related]
15. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
[TBL] [Abstract][Full Text] [Related]
16. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
Karreth FA; DeNicola GM; Winter SP; Tuveson DA
Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
[TBL] [Abstract][Full Text] [Related]
17. Protein phosphatase 2A positively regulates Ras signaling by dephosphorylating KSR1 and Raf-1 on critical 14-3-3 binding sites.
Ory S; Zhou M; Conrads TP; Veenstra TD; Morrison DK
Curr Biol; 2003 Aug; 13(16):1356-64. PubMed ID: 12932319
[TBL] [Abstract][Full Text] [Related]
18. Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF.
Hu J; Yu H; Kornev AP; Zhao J; Filbert EL; Taylor SS; Shaw AS
Proc Natl Acad Sci U S A; 2011 Apr; 108(15):6067-72. PubMed ID: 21441104
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.
Yaeger R; Yao Z; Hyman DM; Hechtman JF; Vakiani E; Zhao H; Su W; Wang L; Joelson A; Cercek A; Baselga J; de Stanchina E; Saltz L; Berger MF; Solit DB; Rosen N
Cancer Res; 2017 Dec; 77(23):6513-6523. PubMed ID: 28951457
[No Abstract] [Full Text] [Related]
20. Expression of kinase suppressor of Ras1 enhances cisplatin-induced extracellular signal-regulated kinase activation and cisplatin sensitivity.
Kim M; Yan Y; Kortum RL; Stoeger SM; Sgagias MK; Lee K; Lewis RE; Cowan KH
Cancer Res; 2005 May; 65(10):3986-92. PubMed ID: 15899786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]